Kaitlyn Kosko

DocwireNews

Patients with NSCLC who have NTRK mutations have a survival advantage with immune checkpoint inhibitors compared with patients who have wild-type NTRK, according to a study conducted in China. These findings were especially true when taking into consideration tumor mutational burden (TMB) and blood TMB (bTMB).Xiaoling Zhang and colleagues analyzed mutation frequency with clinical characteristics and patient survival in a cohort (n=1567) from the cBioPortal. Patients had NTRK1 mutation (3.5%), NTRK2 mutation (1.5%), or NTRK3 mutation (5.0%). They discovered that patients with an NTRK mutation had worse median OS than patients with wild-type NTRK (18.9 months vs 21.2 months, respectively).&ldquo;These findings suggested that patients with NTRK family mutations had worse prognosis compared [with wild-type] patients if not defining specific treatments,&rdquo; the researchers said.However, when treated with an immune checkpoint inhibitor, patients who were NTRK mutant versus wild-type lived longer. Zhang observed these data using two cohorts (Samstein [n=350]) and (OAK/POPLAR [n=569]).Median OS was 21 months for NTRK mutant compared with 11 months for wild-type NTRK in the Samstein cohort. All patients had advanced NSCLC and 94% received anti-PD-1/PD-L1 monotherapy.In the OAK-POPLAR cohort, identical median OS was detected between patients with an NTRK mutation and those who were wild-type (13.2 months vs 13.5 months, respectively). All patients were treated with atezolizumab (Tecentriq). Furthermore, while these patients had similar PD-L1 expression, the NTRK mutation group had higher TMB, bTMB, and enriched antitumor immunity.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

How Immune Checkpoint Inhibitors Affect NTRK-Mutant NSCLC

Non-Small Cell Lung Cancer

Patients with NSCLC who have NTRK mutations have a survival advantage with immune checkpoint inhibitors.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe